Life Sciences Tools and Services
Company Overview of Aphios Corporation
Aphios Corporation develops enabling biotechnology and nanotechnology drug delivery platforms. It also manufactures quality-of-life medicines for health maintenance; research chemicals for standards; and active pharmaceutical ingredients for pharmaceuticals. The company’s therapeutic products include Zindol, an enhanced ginger product; APH-0703, a potent protein kinase C (PKC) activator; APH-0812, a combination therapy consisting of PKC modulators with or without HDAC inhibitors; AMPI-109, a nontoxic Vitamin D3 derivative for hormone refractory prostate cancer; APH-0911, a nanotechnology formulation of Taxotere prodrug with sugar side chain that improves the oral bioavailability of water-sol...
3-E Gill Street
New Boston Park
Woburn, MA 01801
Founded in 1993
Key Executives for Aphios Corporation
Founder, Chairman of The Board, Chief Executive Officer and President
Compensation as of Fiscal Year 2016.
Aphios Corporation Key Developments
Aphios Pharma Presents at The NYC Family Office & Wealth Management Meeting, Mar-28-2017 11:55 AM
Mar 25 17
Aphios Pharma Presents at The NYC Family Office & Wealth Management Meeting, Mar-28-2017 11:55 AM. Venue: Pepper Hamilton LLp, New York, New York, United States. Speakers: Karina D. Allen-Ludwig, Scientist.
Aphios Pharma to Develop FDA-Approved, Cannabis-Based Drugs for Opioid Addiction, Epilepsy and Multiple Sclerosis
Feb 22 17
Aphios Corporation announced that it is spinning-off Aphios® Pharma to develop FDA-approved, cannabis-based drugs for treating highly unmet Central Nervous System (CNS) disorders such as opioid addiction, epilepsy including childhood epilepsy and multiple sclerosis that are only partially and anecdotally addressed by medical marijuana. Opioid addiction has grown to epidemic proportions. Current statistics indicate that heroin overdoses have more than tripled over the last four years. Between 26.4 million and 36 million people abuse opioids worldwide with an estimated 2.1 million people in the US reporting substance abuse disorders related to prescription opioid pain relievers with an estimated 467,000 addicted to heroin. Apart from the enormous burdens on the individuals, families and communities, the US economic burden is significant amounting to an estimated $78 billion annually. However, there is insufficient rigorous clinical evidence of the efficacy of cannabinoids for opioid addiction and other significant CNS disorders, and a lack of availability of pharmaceutical-grade cannabinoids to conduct rigorous clinical trials. These studies must also be conducted in the strict regulatory environments of both the Drug Enforcement Agency (DEA) and the Food and Drug Administration (FDA).
Aphios Corporation Presents at 2016 BIO Investor Forum, Oct-18-2016 09:30 AM
Sep 15 16
Aphios Corporation Presents at 2016 BIO Investor Forum, Oct-18-2016 09:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|